June 11, 2012 | Foundation Medicine and Novartis are partnering on cancer drug testing. Novartis plans to use Foundation's technology (see, "Laying the Foundation for Next-Gen Cancer Diagnostics") as part of its cancer trial enrollment process over the next three years, focusing on Phase 1 and 2 oncology clinical programs. The two groups began a pilot program 18 months ago that has generated "very interesting data." Foundation Medicine recently made its genomic profile for patients commercially available. Foundation Medicine Statement [PDF]